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Ataxia-telangiectasia (AT), a rare autosomal recessive
human genetic disorder, is a syndrome remarkable for
its pleiotropic phenotype. The hallmark features of AT
are degenerative neurological function, particularly in
the cerebellum, and oculocutaneous telangiectasias.
These features are often accompanied by immunodefi-
ciency, infertility, small size, sensitivity to the effects of
ionizing radiation (IR), and increased predisposition to
cancer. Cell lines derived from patients with AT also
display characteristic abnormalities, including poor
growth, premature senescence, sensitivity to IR, and fail-
ure to establish effective cell-cycle arrest after genotoxic
insult. Mice deficient in Atm—the mouse homologue
(Pecker et al. 1996) of ATM, the gene mutated in AT
(Savitsky et al. 1995)—display a similar pleiotropic phe-
notype in vivo and in vitro (Barlow et al. 1996; Elson
et al. 1996; Xu et al. 1996; Herzog et al. 1998). Thus,
ATM is crucial for the maintenance of normal function
in a wide variety of mitotic, postmitotic, and meiotic cell
types and tissues.
Determining how the loss of function of a single gene
product can lead to such diverse phenotypes in humans
and mice is central to understanding the molecular na-
ture of the AT disorder. An understanding of proteins
that directly interact with ATM, the pathways that these
interacting proteins modulate, and the functional con-
sequences attributable to ATM’s absence will likely clar-
ify the pathophysiological disturbances that result in the
AT phenotype. In particular, what biological functions
are disrupted in various tissues when ATM is missing?
Several recent studies have identified direct down-
stream targets of ATM, and in some cases, clues about
the biological function of these interactions are begin-
ning to emerge. In this review we have placed these find-
ings in the context of the pleiotropic phenotype dis-
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played by patients with AT and by Atm-deficient mice.
For more comprehensive reviews on AT, see Shiloh
(1997) and Rotman and Shiloh (1998).
ATM and Its Product
Disease-causing mutations in ATM are found scat-
tered throughout its coding sequence and include both
point mutations and intragenic deletions (Gilad et al.
1996). As is common when mutations introduce pre-
mature termination codons, no truncated ATM gene
product is detected in AT cells that harbor frameshift
mutations within ATM (Brown et al. 1997; Watters et
al. 1997); such mutations constitute the clear majority
of ATM mutations mapped to date (Gilad et al. 1996).
Thus, AT is likely caused by complete loss of ATM func-
tions, and this view is supported by rescue experiments
using full-length recombinant ATM in AT cell lines
(Zhang et al. 1997; Ziv et al. 1997) and by depletion
of endogenous ATM in normal cells determined by
means of antisense approaches (Zhang et al. 1998).
The ATM protein possesses a carboxy-terminal kinase
domain with distinct homology to the lipid kinase phos-
photidylionsitol-3 kinase (PI-3K) and the serine/threo-
nine protein kinase DNA-dependent protein kinase
(DNA-PK). ATM is one of a growing family of high–
molecular-weight kinases that are conserved throughout
eukaryotic evolution from yeast to mammals (Zakian
1995). Analyses of many of the ATM family members
and related lipid kinases show that they regulate diverse
processes such as mitotic checkpoints, meiosis, the mon-
itoring of telomere length, V(D)J recombination, apop-
tosis, proliferation, and membrane trafficking. On the
basis of the AT phenotype, we may assume that the
diverse functions of these family members overlap sub-
stantially with the inferred function of ATM.
Despite the homology to PI-3K, ATM does not appear
to possess lipid kinase activity, but ATM and several of
its relatives are known from both in vitro and in vivo
studies to act as serine-specific protein kinases (Hartley
et al. 1995; Keegan et al. 1996; Baskaran et al. 1997;
Banin et al. 1998; Canman et al. 1998; Gately et al.
1998). Given that every member of the ATM kinase
family investigated so far exhibits a strict requirement
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Figure 1 Function of nuclear ATM after DNA damage. The catalytic activity of ATM has been shown to be upregulated after the
introduction of double-strand breaks into the genome. Currently, there are three recognized downstream targets for ATM phosphorylation
within the nucleus: c-Abl, p53, and the p34 subunit of RPA. Phosphorylation of these proteins results in the indicated cellular responses. Note:
ATM interacts with the cytoplasmic protein b-adaptin; however, it is unclear whether this molecule is a target for ATM phosphorylation.
for an intact kinase domain (see Cliby et al. 1998 and
references therein), it seems likely that ATM-associated
catalytic activity is critical to its function.
ATM is a single high–molecular-weight phosphopro-
tein (∼350 kD; Chen and Lee 1996; Lakin et al. 1996;
Brown et al. 1997; Watters et al. 1997) that is ubiqui-
tously expressed, although at heterogeneous levels in dif-
ferent cell and tissue types. ATM is present predomi-
nantly within the nucleus of cultured human cells (Chen
and Lee 1996; Lakin et al. 1996; Brown et al. 1997;
Watters et al. 1997), consistent with the proposed role
of ATM in cellular response to DNA damage, but a
fraction of ATM is also present in the cytoplasm. Several
nuclear substrates have been identified for ATM (fig. 1),
and it is likely that defects in the ATM-dependent phos-
phorylation of these molecules may explain some of the
effects of ATM deficiency in individuals with AT and in
mouse models of the disease.
c-Abl
The first direct target identified for ATM catalytic ac-
tivity was the nuclear tyrosine kinase c-Abl. IR-induced
c-Abl activation is defective in AT cells lines (Shafman
et al. 1997) and in cells or tissues from Atm-deficient
mice (Baskaran et al. 1997). Both genetic and biochem-
ical approaches determined that an SH3 motif of c-Abl
binds directly to a proline-rich region of the ATM mol-
ecule (Shafman et al. 1997), consistent with a direct
stimulation of c-Abl activity by ATM. In addition, the
minimal kinase domain of ATM can phosphorylate
c-Abl Ser465 directly, and such modification activates
c-Abl in vitro (Baskaran et al. 1997). The biological
consequences of this interaction and activation are not
fully understood. Still, the identification of RNA poly-
merase II as a c-Abl substrate suggests that an ATM/
c-Abl–dependent pathway could modulate cellular pat-
terns of gene expression in response to genome damage.
ATM-dependent activation of c-Abl is unlikely to result
in cell-cycle arrest, since Abl-deficient cells activate IR-
induced cell-cycle checkpoints normally (Baskaran et al.
1997).
Replication Protein A
Another candidate target for regulation by nuclear
ATM is the p34 subunit of replication protein A (RPA).
RPA, a known substrate for ATM-mediated phosphor-
ylation in vitro (Gately et al. 1998), is a heterotrimeric
single-stranded DNA binding complex involved in DNA
replication, repair, and recombination. Several groups
have shown that, after IR exposure, p34 fails to become
phosphorylated in AT cells (Liu and Weaver 1993; Mor-
gan and Kastan 1997). These observations led to spec-
ulation that this deficiency is responsible for the failure
of AT cells to arrest in S-phase in response to IR (Liu
and Weaver 1993). However, Morgan and Kastan
(1997) found that p34 phosphorylationwas not required
for S-phase arrest, leaving unclear the physiological out-
come of this modification.
p53
Perhaps the most compelling potential target for nu-
clear ATM is the tumor suppressor protein p53, since it
has long been known that AT cells show irradiation-
induced cell-cycle checkpoint defects and, after IR, fail
to upregulate p53 to levels observed in normal cells (Kas-
tan et al. 1992). p53, acting as a transcription factor,
plays a crucial role in several cellular reponses triggered
by IR exposure. Among the proteins whose expression
p53 is known to induce are p21WAF1/CIP1—a potent in-
hibitor of cyclin-dependent kinase activity—and Bax,
which activates apoptosis. Recently, we demonstrated in
vivo that ATM is required in the thymus for cell-cycle
arrest after IR exposure, although, as we and others
found, IR-induced apoptosis in thymocytes is indepen-
dent of ATM (Barlow et al. 1997a; Herzog et al. 1997).
At the molecular level, thymocytes from irradiatedAtm-
deficient mice show markedly reduced p53-dependent
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induction of p21WAF1/CIP1, consistent with the lack of ap-
propriate cell-cycle arrest after irradiation. Conversely,
both the rate of apoptosis and the p53-dependent in-
duction of Bax in thymocytes from irradiated mice are
normal (Barlow et al. 1997a;). IR-induced apoptosis is
reduced, however, in the brains of newborn Atm-defi-
cient mice (Herzog et al. 1998), indicating that the func-
tional requirement for ATM in apoptotic pathways may
differ among cell types. Taken together, these findings
suggest that ATM exerts a differential effect on p53 to
specify timely transcriptional induction of p21WAF1/CIP1
and normal cell-cycle arrest in response toDNAdamage,
but that the role of ATM in apoptosis is dispensable in
some cell types.
Consistent with these functional studies, Watters et al.
(1997) report that ATM interacts with p53, and the
ATM-related protein DNA-PK is also known to bind
and phosphorylate p53 directly (Hartley et al. 1995).
After DNA damage, p53 is phosphorylated on Ser15
(Shieh et al. 1997; Siciliano et al. 1997). The rate of this
modification is lower in AT cell lines than in wild-type
cell lines (Siciliano et al. 1997), indicating that some of
the relevant kinase activity requires ATM expression and
that modification of p53 may be a common feature of
the ATM kinase family. Support for the hypothesis that
p53 is a direct catalytic substrate of ATM comes from
recent reports demonstrating that endogenous or recom-
binant ATM phosphorylates p53 on Ser15 and that
ATM displays increased kinase activity in response to
IR or to the radiomimetic compound neocarzinostatin
(Banin et al. 1998; Canman et al. 1998), but not to UV
irradiation. This finding is consistent with the longstand-
ing observation that AT cells are defective in their re-
sponse to double-strand breaks (DSBs) within their ge-
nome, the type of damage caused by IR, but that they
possess normal responses to base damage caused by
agents such as UV irradiation or alkylating agents. An-
other ATM family member, ATR/FRP-1 (Keegan et al.
1996; Cliby et al. 1998), also phosphorylates p53 on
Ser15, but at only ∼5% of the activity, when assayed
under the same conditions (Canman et al. 1998).
This body of evidence makes a convincing case that
ATM directly phosphorylates p53 Ser15 in response to
genotoxic insults that induce DSBs. Intriguingly, this
modification of p53 may activate cell-cycle checkpoints,
since mutation of Ser15 leads to checkpoint defects (Fis-
cella et al. 1993). This possibility is consistent with ob-
servations that p53-dependent cell-cycle checkpoint re-
sponses to IR are defective in the thymus of Atm-
deficient mice (Barlow et al. 1997a).
b-Adaptin
Neither the involvement of ATM in post-IR activation
of cell-cycle checkpoints nor any of the other known
intranuclear events mediated by ATM suggest any ob-
vious explanation for the neuronal dysfunction and de-
generation seen in individuals with AT. However, along
with the finding that ATM is a nuclear protein, this
molecule was also found to cofractionate (Lakin et al.
1996; Brown et al. 1997; Watters et al. 1997) and co-
localize (Watters et al. 1997) with cytoplasmic vesicles.
The cytoplasmic pool of ATM does not appear to change
in quantity or localization in response to IR (Brown et
al. 1997; Watters et al. 1997), so it is unlikely that ATM
is recruited to the nucleus after DNA damage; hence any
role of cytoplasmic ATM is likely to be independent of
its function in genome surveillance.
Lending a biochemical basis to the observation that
cells contain microsomal ATM is the recent finding that
ATM binds to the vesicle-associated protein b-adaptin
(Lim et al. 1998). b-Adaptin is a component of the AP-
2 adaptor complex, which interacts with several proteins
that are important in membrane trafficking and cell sig-
naling and in endocytosis of clathrin-coated vesicles.
Several ATM-related lipid kinases, in particular Vps34
and PI-3K, also play a critical role in stimulating vesicle
and protein transport (DeCamilli et al. 1996).
The consequences of the interaction between ATM
and b-adaptin are unknown, but it is tempting to spec-
ulate that the cytoplasmic fraction of ATM may act in
vesicle transport and that this function is disrupted in
patients with AT. Thus, the neurological dysfunction
seen in both AT patients and Atm-deficient mice, as well
as the neurodegeneration displayed by AT patients,
could result from abnormal axonal or synaptic trans-
port. Indeed, ATM is present primarily in the cyto-
plasm of human (Oka and Takashima 1998) and mouse
neurons, and neurons in Atm-deficient mice have an in-
creased number of lysosomes, as judged by electron mi-
croscopy (C. Barlow, unpublished data). These obser-
vations are consistent with the hypothesis that ATM is
important in vesicle transport, perhaps via interaction
with b-adaptin or related proteins such as b-NAP, and
that disruption of this function may contribute to the
neurological phenotype of patients with AT and of Atm-
deficient mice.
Forming a Basis for the Pleiotropic Nature of the AT
Disorder
The recent studies described in this review indicate
that ATM interacts with multiple downstream targets.
Since these targets are located both in the nucleus and
in the cytoplasm, this protein is most likely involved in
several distinct signaling pathways. Now that some of
these targets have been identified, it is hoped that they
will provide an entry point to the pathways regulated
by ATM in various tissues in vivo. For example, in the
thymus, p53 is phosphorylated directly by ATM after
IR, probably in the nucleus, leading to transcriptional
activation of p21Waf1/Cip1 and consequential cell-cycle ar-
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rest. In the absence of ATM, this pathway is disrupted,
and this defect perhaps results in the immunodeficiency
and abnormal cellular responses to IR seen in patients
with AT. Furthermore, the infertility noted in both AT
patients and Atm-deficient mice is due to abnormal mei-
otic progression and subsequent germ-cell degeneration,
a phenotype that is partially corrected by concomitant
loss of p53 and p21 function (Barlow et al. 1997b). ATM
interactions with b-adaptin in the cytoplasm might me-
diate axonal transport and vesicle trafficking in the cen-
tral nervous system and so account for the neuronal
dysfunction and eventual neurodegeneration seen in AT.
In this view, the phenotypic pleiotropy of AT results
from the fact that different tissues express differentATM
targets and perhaps also express a different complement
of ATM family members whose functions may overlap
with those of ATM. This model is attractive and testable,
given the existence of mouse models of AT that permit
various tissues, including brain, to be isolated and stud-
ied. In addition, genetic manipulations will allow the
breeding of mice harboring mutations in multiple genes
for putative targets of ATM. Such analysis should clarify
the role of the various genes in specific AT phenotypes.
As more targets of ATM (and ATM-related kinases) are
defined and scrutinized, we should develop a deeper un-
derstanding of the molecular basis of the pleiotropic AT
phenotype. Our hope is that this understanding will pro-
vide a framework for developing therapies for this dev-
astating disorder.
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